Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound sleep: new device aims to boost brain health with targeted tones

NCT ID NCT06669546

Symptom relief Sponsor: University of Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a portable device that plays soft sounds during deep sleep to improve memory and slow cognitive decline in older adults. Sixty participants aged 60-85 with mild memory problems will use the device at home for two 4-week periods. The goal is to see if enhancing slow-wave sleep can protect the brain and reduce dementia risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Phase-locked auditory stimulation (PLAS) via the SleepLoop device
What this could lead to
If it works, this could lead to an affordable, home-use treatment that helps maintain brain health and slows memory loss in older adults.
What could go wrong
This is an early-stage study with only 60 participants, and it tests a device over a short period. The real-world benefits may be small or not last long.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Age between 60 and 85 years * Cognitive impairment (subjective and/or MoCA between 23-26) * Native German speakers or comparably fluent * Normal or corrected-to-normal vision. * Intact hearing * A close cohabitant (partner/sibling) should be present to support participants in using study materials/devices. Exclusion Criteria: * Insomnia assessed by the Regensburg Insomnia Scale (RIS; Crönlein et al., 2013) * Restless leg syndrome assessed by questions concerning typical symptoms. * Sleep apnoea assessed by the Berlin Questionnaire (BQ; Netzer et al., 1999) * Severely irregular sleep patterns assessed by the RIS and the Pittsburgh sleep quality index (PSQI; Buysse et al., 1989) * Symptoms of depression (Geriatric Depression Scale (GDS; Yesavage et al., 1982) ≥ 5) * History of untreated severe neurological and psychiatric diseases * Alcohol or substance abuse * Use of medication acting on the central nervous system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Cognitive decline Cognitive impairment, mild Mild cognitive impairment (MCI) Subjective cognitive decline (SCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Old Age Psychiatry and Psychotherapy, University of Bern

    RECRUITING

    Bern, 3000 60, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.